

Franco Cecchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3370255/publications.pdf>

Version: 2024-02-01

34
papers

9,941
citations

257101

24
h-index

414034

32
g-index

34
all docs

34
docs citations

34
times ranked

7713
citing authors

#	ARTICLE	IF	CITATIONS
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.	1.0	3,469
2	Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2003, 348, 295-303.	13.9	1,217
3	Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. <i>Circulation</i> , 2006, 114, 2232-2239.	1.6	830
4	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2014, 130, 484-495.	1.6	783
5	Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2005, 46, 470-476.	1.2	677
6	Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2003, 349, 1027-1035.	13.9	670
7	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2018, 138, 1387-1398.	1.6	468
8	Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2008, 52, 559-566.	1.2	269
9	Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 36.	1.2	239
10	Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1043-1048.	1.2	208
11	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). <i>Circulation</i> , 2018, 137, 1015-1023.	1.6	149
12	Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. <i>International Journal of Cardiology</i> , 2014, 177, 400-408.	0.8	119
13	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	103
14	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. <i>European Journal of Heart Failure</i> , 2016, 18, 1106-1118.	2.9	101
15	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. <i>JAMA Cardiology</i> , 2018, 3, 520.	3.0	78
16	Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. <i>Nature Reviews Cardiology</i> , 2009, 6, 317-321.	6.1	72
17	Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1090-1096.	2.8	68
18	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2015, 8, 1014-1021.	1.6	67

#	ARTICLE	IF	CITATIONS
19	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. <i>Genetics in Medicine</i> , 2019, 21, 284-292.	1.1	54
20	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. <i>Heart Rhythm</i> , 2016, 13, 457-463.	0.3	46
21	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. <i>Circulation</i> , 2019, 139, 830-833.	1.6	43
22	Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: A cardiac magnetic resonance study. <i>International Journal of Cardiology</i> , 2013, 167, 1038-1045.	0.8	38
23	Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 231, 115-119.	0.8	30
24	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 117, 1151-1159.	0.7	25
25	Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®). <i>International Journal of Cardiology</i> , 2017, 236, 249-252.	0.8	23
26	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2019, 291, 77-82.	0.8	22
27	Common presentation of rare diseases: Left ventricular hypertrophy and diastolic dysfunction. <i>International Journal of Cardiology</i> , 2018, 257, 344-350.	0.8	19
28	Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 273, 155-161.	0.8	17
29	Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. <i>Global Cardiology Science & Practice</i> , 2012, 2012, 9.	0.3	13
30	Subcutaneous implantable cardioverter defibrillator in cardiomyopathies and channelopathies. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 633-642.	0.6	8
31	Arrhythmias due to Inherited and Acquired Abnormalities of Ventricular Repolarization. <i>Cardiac Electrophysiology Clinics</i> , 2019, 11, 345-362.	0.7	8
32	Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients. <i>European Heart Journal Digital Health</i> , 2021, 2, 175-178.	0.7	8
33	Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?. <i>International Journal of Cardiology</i> , 2017, 246, 55.	0.8	0
34	Biventricular arrhythmogenic cardiomyopathy: a paradigmatic case. <i>ScienceOpen Research</i> , 2015, .	0.6	0